Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.
The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback